FR08C0015I1 - - Google Patents

Info

Publication number
FR08C0015I1
FR08C0015I1 FR08C0015C FR08C0015I1 FR 08C0015 I1 FR08C0015 I1 FR 08C0015I1 FR 08C0015 C FR08C0015 C FR 08C0015C FR 08C0015 I1 FR08C0015 I1 FR 08C0015I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25544691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR08C0015I1 publication Critical patent/FR08C0015I1/fr
Application granted granted Critical
Publication of FR08C0015I2 publication Critical patent/FR08C0015I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
FR08C0015C 1997-12-24 2008-04-17 Dérivés de sulfamides en tant que prodrogues d'inhibiteurs de protéase d'aspartyl Active FR08C0015I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/998,050 US6436989B1 (en) 1997-12-24 1997-12-24 Prodrugs of aspartyl protease inhibitors

Publications (2)

Publication Number Publication Date
FR08C0015I1 true FR08C0015I1 (fr) 2008-05-30
FR08C0015I2 FR08C0015I2 (fr) 2009-10-30

Family

ID=25544691

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0015C Active FR08C0015I2 (fr) 1997-12-24 2008-04-17 Dérivés de sulfamides en tant que prodrogues d'inhibiteurs de protéase d'aspartyl

Country Status (43)

Country Link
US (5) US6436989B1 (fr)
EP (2) EP0933372B1 (fr)
JP (3) JP3736964B2 (fr)
KR (1) KR100520737B1 (fr)
CN (2) CN100503589C (fr)
AP (1) AP1172A (fr)
AR (1) AR017965A1 (fr)
AT (1) ATE382042T1 (fr)
AU (1) AU755087B2 (fr)
BG (1) BG64869B1 (fr)
BR (1) BR9814480A (fr)
CA (1) CA2231700C (fr)
CO (1) CO4990992A1 (fr)
CZ (1) CZ301653B6 (fr)
DE (2) DE122008000021I2 (fr)
DK (1) DK0933372T3 (fr)
EA (1) EA003509B1 (fr)
EE (1) EE04466B1 (fr)
ES (1) ES2299193T3 (fr)
FR (1) FR08C0015I2 (fr)
HK (1) HK1021737A1 (fr)
HU (2) HU229596B1 (fr)
ID (1) ID24962A (fr)
IL (2) IL136941A0 (fr)
IS (1) IS2817B (fr)
LU (1) LU91426I2 (fr)
ME (1) MEP82008A (fr)
MY (1) MY131525A (fr)
NL (1) NL300339I2 (fr)
NO (2) NO326265B1 (fr)
NZ (1) NZ505776A (fr)
OA (1) OA11468A (fr)
PE (1) PE20000048A1 (fr)
PL (1) PL202845B1 (fr)
PT (1) PT933372E (fr)
RS (1) RS52483B (fr)
SI (1) SI0933372T1 (fr)
SK (1) SK287123B6 (fr)
TR (1) TR200002615T2 (fr)
TW (1) TW486474B (fr)
UA (1) UA72733C2 (fr)
WO (1) WO1999033815A1 (fr)
ZA (1) ZA9811830B (fr)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9911612A (pt) 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
BR0207862A (pt) 2001-02-14 2004-06-22 Tibotec Pharm Ltd Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
CZ303139B6 (cs) 2001-04-09 2012-04-25 Tibotec Pharmaceuticals Ltd. 2-(substituovaný amino)-benzoxazolsulfonamidový derivát, farmaceutická kompozice s jeho obsahem a zpusob in vitro inhibice retrovirové replikace
AR035970A1 (es) 2001-05-11 2004-07-28 Tibotec Pharm Ltd 2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos
US7576084B2 (en) * 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
JP2005529062A (ja) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
EP1465631B1 (fr) 2001-12-20 2010-02-24 OSI Pharmaceuticals, Inc. Composes pyrimidine antagonistes selectifs des recepteurs a2b, leur synthese et leur utilisation
AU2002361235B2 (en) 2001-12-21 2008-07-24 Tibotec Pharmaceuticals Ltd. Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
BR0309557A (pt) * 2002-04-26 2005-03-01 Gilead Sciences Inc Inibidores da transcriptase reversa não nucleosìdeos
SI1517899T1 (sl) 2002-05-17 2008-02-29 Tibotec Pharm Ltd Substituirani benzoksazol sulfonamidi sirokega spektra, ki so HIV proteazni inhibitorji
WO2004016619A1 (fr) 2002-08-14 2004-02-26 Tibotec Pharmaceuticals Ltd. Oxindole sulfonamides substitues inhibiteurs a large spectre de la protease du vih
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2425031A1 (fr) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Compositions pharmaceutiques
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
AU2004233897A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
EP2292590A3 (fr) * 2003-07-09 2012-05-02 Paratek Pharmaceuticals, Inc. Promédicaments de composés de tétracycline 9-aminométhylé
EA201001081A1 (ru) 2003-07-09 2011-02-28 Пэрэтек Фамэсьютикэлс, Инк. Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
MY148233A (en) * 2003-12-15 2013-03-29 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
CA2549869C (fr) 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Anti-proliferants a base de derives pyrido- et pyrimidopyrimidine
NZ547907A (en) 2003-12-22 2010-07-30 Gilead Sciences Inc 4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
KR101229431B1 (ko) 2004-07-06 2013-02-04 아보트 러보러터리즈 Ｈｉｖ 프로테아제 억제제의 프로드럭
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
EP2165709B1 (fr) * 2004-08-02 2016-03-16 Ambrilia Biopharma Inc. Composition pharmaceutique comprenant un composé à base de lysine et un agent VIH-antiviral ou antirétroviral
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
US20070292478A1 (en) 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
DK1941798T3 (da) 2004-12-17 2012-08-27 Devgen Nv Nematicide præparater
BRPI0606318B8 (pt) * 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
US20080194554A1 (en) * 2005-03-11 2008-08-14 Mclean Ed W Hiv Protease Inhibitors
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
ES2539527T3 (es) 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
US8003627B2 (en) 2005-10-21 2011-08-23 Universiteit Antwerpen Urokinase inhibitors
AR058238A1 (es) 2005-11-28 2008-01-23 Tibotec Pharm Ltd Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
AR057182A1 (es) 2005-11-28 2007-11-21 Tibotec Pharm Ltd Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2632095A1 (fr) * 2005-11-30 2007-06-07 Ambrilia Biopharma Inc. Promedicaments d'inhibiteurs d'aspartyl protease a base de lysine et leurs procedes de fabrication
US20100004206A1 (en) * 2005-12-27 2010-01-07 Makoto Komatsu Water-soluble benzoazepine compound and its pharmaceutical composition
AU2007274284B2 (en) 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
WO2008028688A2 (fr) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Composés et procédés associés à des agents étiquetés 18f
ES2628730T3 (es) * 2006-09-21 2017-08-03 Taimed Biologics, Inc. Inhibidores de proteasa
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
ES2562218T3 (es) 2007-07-27 2016-03-03 Janssen Pharmaceutica, N.V. Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
EP2053033A1 (fr) 2007-10-26 2009-04-29 Bayer Schering Pharma AG Composants à utiliser dans l'imagerie, le diagnostic et/ou le traitement des maladies du système nerveux central ou des tumeurs
EP2100900A1 (fr) 2008-03-07 2009-09-16 Universitätsspital Basel Conjugués d'antagoniste de peptide analogue de bombésine
WO2009112439A1 (fr) 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases
WO2009114151A1 (fr) * 2008-03-12 2009-09-17 Nektar Therapeutics Conjugués oligomères-acides aminés et oligomères-atazanavir
EP2116236A1 (fr) 2008-04-21 2009-11-11 Université de Mons-Hainaut Dérivés de bisbenzamidine pour une utilisation en tant qu'antioxydants
EA018308B1 (ru) 2008-07-08 2013-07-30 Джилид Сайэнс, Инк. Соли соединений ингибиторов вич
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
WO2010134045A1 (fr) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Fosamprenavir calcique amorphe
EP2440249A2 (fr) 2009-06-12 2012-04-18 Nektar Therapeutics Conjugués covalents comprenant un inhibiteurs de protéase, un oligomère non-peptidique soluble dans l'eau et une partie lipophilique
CA2774483C (fr) 2009-09-16 2014-11-18 Ranbaxy Laboratories Limited Procede pour preparer du fosamprenavir calcium
WO2011061590A1 (fr) 2009-11-17 2011-05-26 Hetero Research Foundation Nouveaux dérivés carboxamides comme inhibiteurs du vih
WO2011061295A1 (fr) 2009-11-19 2011-05-26 Blue Medical Devices Bv Cathéter à ballonnet médical extensible à libération de composition et profil étroit
WO2011085130A1 (fr) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
WO2011141515A1 (fr) 2010-05-14 2011-11-17 Bayer Pharma Aktiengesellschaft Agents de diagnostic pour l'imagerie d'amyloïdes bêta
WO2011158259A1 (fr) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Nouveau procédé pour la préparation du (1s, 2r)-3-[[(4-aminophényl)sulfonyl] (isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate de (3s)-tétrahydrofurane-3-yle et ses sels pharmaceutiquement acceptables
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
EP2614055A2 (fr) 2010-09-10 2013-07-17 Lupin Limited Procédé de préparation de calcium de fosamprenavir sensiblement pur et de ses intermédiaires
GB201019043D0 (en) 2010-11-10 2010-12-22 Protea Biopharma N V Use of 2',5'-oligoadenylate derivative compounds
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) * 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
KR102395085B1 (ko) 2011-06-21 2022-05-09 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
EP3597750B1 (fr) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Arnsi de serpina1 :compositions de matière et procédés de traitement
US9309213B2 (en) 2011-07-11 2016-04-12 Purdue Research Foundation C-3 substituted bicyclooctane based HIV protease inhibitors
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
IN2012DE00082A (fr) 2012-01-10 2015-05-01 Council Scient Ind Res
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
EP2700396A3 (fr) 2012-06-20 2015-04-29 Sylphar Nv Bande pour l'administration de compositions pour soins buccaux
WO2014059034A2 (fr) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Précurseurs et biosynthèse de nad pour le traitement et la prévention du cancer et de sa prolifération
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
RS56783B9 (sr) 2012-12-05 2021-12-31 Alnylam Pharmaceuticals Inc Sastavi pcsk9 irnk i postupci njihovih primena
CA2904654C (fr) 2013-03-14 2023-12-05 Alnylam Pharmaceuticals, Inc. Compositions d'arni du constituant c5 du complement et leurs procedes d'utilisation
HUE038146T2 (hu) 2013-05-22 2018-09-28 Alnylam Pharmaceuticals Inc Serpina1 IRNS készítmények és eljárások alkalmazásukra
BR112015029276B1 (pt) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
SG11201604692UA (en) 2013-12-12 2016-07-28 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN106103718B (zh) 2014-02-11 2021-04-02 阿尔尼拉姆医药品有限公司 己酮糖激酶(KHK)iRNA组合物及其使用方法
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
MX2016015126A (es) 2014-05-22 2017-02-23 Alnylam Pharmaceuticals Inc Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
WO2016003450A1 (fr) 2014-07-01 2016-01-07 The Regents Of The University Of California Inhibiteurs de pkc-epsilon
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
WO2016040589A1 (fr) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
EP3207138B1 (fr) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques de ciblage d'acide aminolévulinique synthase-1 (alas1) et utilisations de ceux-ci
EP3212196A4 (fr) 2014-10-29 2018-07-11 Wisconsin Alumni Research Foundation Inhibiteurs de protéase de vih à base d'acide borique
EP3212794B1 (fr) 2014-10-30 2021-04-07 Genzyme Corporation Agents polynucléotidiques ciblant serpinc 1 (at3) et leurs méthodes d'utilisation
WO2016081444A1 (fr) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Compositions d'arni d'apolipoprotéine c3 (apoc3) et procédés d'utilisation de ces compositions
WO2016083490A1 (fr) 2014-11-27 2016-06-02 Remynd Nv Composés pour le traitement de maladies associées à la substance amyloïde
CA2976445A1 (fr) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Compositions d'arni du gene codant pour la proteine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs procedes d'utilisation
TWI723986B (zh) 2015-04-13 2021-04-11 美商阿尼拉製藥公司 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法
AU2016255853B2 (en) 2015-04-28 2021-08-05 Newsouth Innovations Pty Limited Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
CN108271386B (zh) 2015-05-06 2022-07-15 阿尔尼拉姆医药品有限公司 因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
WO2016205323A1 (fr) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant l'hydroxyacide oxydase (glycolate oxydase, hao1) et procédés d'utilisation de ceux-ci
WO2017048620A1 (fr) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Agents de polynucléotide ciblant un domaine de phospholipase de type patatine contenant 3 (pnpla3) et leurs procédés d'utilisation
EP3349757A1 (fr) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
RU2754188C2 (ru) 2015-12-07 2021-08-30 Джензим Корпорейшн Способы и композиции для лечения ассоциированного с serpinc1 расстройства
JP2018536689A (ja) 2015-12-10 2018-12-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
EP3621963B1 (fr) 2017-05-11 2024-01-24 Remynd N.V. Composés pour le traitement de l'épilepsie, de troubles neurodégénératifs et d'autres troubles du système nerveux central
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
EP3704252A1 (fr) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c3 et leurs procédés d'utilisation
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
MX2021008628A (es) 2019-01-16 2021-11-17 Genzyme Corp Composiciones de arni para serpinc1 y metodos de uso de las mismas.
WO2021154941A1 (fr) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Compositions d'arni du composant c5 du complément destinées à être utilisées dans le traitement de la sclérose latérale amyotrophique (sla)
AU2021225333A1 (en) 2020-02-24 2022-08-11 Katholieke Universiteit Leuven Pyrrolopyridine and imidazopyridine antiviral compounds
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
AU2021405511A1 (en) 2020-12-22 2023-06-22 Luxembourg Institute Of Health (Lih) Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
EP4301369A1 (fr) 2021-03-04 2024-01-10 Universiteit Antwerpen Inhibiteurs d'erbb4 (her4) à base de quinazolin-4-one et de thiéno[2,3-d]pyrimidin-4-one destinés à être utilisés dans le traitement du cancer
US20240238460A1 (en) 2021-05-31 2024-07-18 Telix Pharmaceuticals (Innovations) Pty Ltd Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
WO2023021132A1 (fr) 2021-08-18 2023-02-23 Katholieke Universiteit Leuven Analogues de ribonucléoside 7-déazapurine 6-substitués et 6,7-disubstitués
WO2023046900A1 (fr) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Analogues de ribonucléosides dirigés contre le sars-cov-2
WO2023241799A1 (fr) 2022-06-15 2023-12-21 Université Libre de Bruxelles Flavanols destinés à être utilisés dans le traitement d'infections rétrovirales
WO2024062043A1 (fr) 2022-09-21 2024-03-28 Universiteit Antwerpen Phénothiazines substituées utilisées en tant qu'inhibiteurs de ferroptose
WO2024175804A1 (fr) 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Modulateurs de transport nucléaire

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
NL8800100A (nl) 1987-01-21 1988-08-16 Sandoz Ag Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
CA1340588C (fr) 1988-06-13 1999-06-08 Balraj Krishan Handa Derive d'aminoacides
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007329A1 (fr) 1989-01-06 1990-07-12 The Regents Of The University Of California Procede de selection de composes pharmacologiquement actifs
US5151438A (en) 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0532693A1 (fr) 1990-06-01 1993-03-24 The Du Pont Merck Pharmaceutical Company 1,4-diamino-2,3-dihydroxybutanes
TW225540B (fr) 1990-06-28 1994-06-21 Shionogi & Co
ES2151618T3 (es) 1990-11-19 2001-01-01 Monsanto Co Inhibidores de proteasas retrovirales.
EP0558603B1 (fr) 1990-11-19 1998-08-26 Monsanto Company Inhibiteurs de proteases retrovirales
CA2096407C (fr) 1990-11-19 2007-10-02 Kathryn Lea Reed Inhibiteurs de la protease des retrovirus
HU9301446D0 (en) 1990-11-19 1993-11-29 Monsanto Co Inhibitors or fetrovirus protease
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
DK0541168T3 (da) 1991-11-08 1998-05-11 Merck & Co Inc HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
CA2131182C (fr) 1992-05-20 2005-04-26 John S. Ng Methode de production d'intermediaires utilises dans la synthese des inhibiteurs de la protease retrovirale
ATE199545T1 (de) 1992-05-21 2001-03-15 Monsanto Co Inhibitoren retroviraler proteasen
KR100296461B1 (ko) 1992-08-25 2001-11-14 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한n-(알카노일아미노-2-히드록시프로필)-술폰아미드
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
AU669223B2 (en) 1992-08-25 1996-05-30 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0610487B1 (fr) * 1992-09-03 1999-11-10 Boehringer Ingelheim Pharma KG Nouveaux derives d'acides amines, leur procede de production et compositions pharmaceutiques contenant ces composes
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US6156768A (en) 1992-10-30 2000-12-05 G. D. Searle & Co. Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
EP0666843B1 (fr) 1992-10-30 1999-08-18 G.D. Searle & Co. Acides sulfonylalcanoylamino hydroxyethylamino sulfamiques utiles comme inhibiteurs de proteases retrovirales
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU6135294A (en) 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (fr) 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
DE69415326T2 (de) 1993-08-24 1999-06-02 G.D. Searle & Co., Chicago, Ill. Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
IL110898A0 (en) 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
IL111584A0 (en) 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
US5527829A (en) 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5750493A (en) 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
BR9814484A (pt) * 1997-12-24 2000-10-10 Vertex Pharma "pró-drogas de inibidores de aspartil protease"
US6319946B1 (en) * 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease

Also Published As

Publication number Publication date
HUP0101831A3 (en) 2002-08-28
CN1284071A (zh) 2001-02-14
UA72733C2 (en) 2005-04-15
BG64869B1 (bg) 2006-07-31
PL202845B1 (pl) 2009-07-31
US20030207871A1 (en) 2003-11-06
HUP0101831A2 (hu) 2002-04-29
DK0933372T3 (da) 2008-04-28
WO1999033815A1 (fr) 1999-07-08
NZ505776A (en) 2003-06-30
IL136941A (en) 2006-06-11
ZA9811830B (en) 2000-06-23
YU39800A (sh) 2004-03-12
US6559137B1 (en) 2003-05-06
HUS1400042I1 (hu) 2017-06-28
NL300339I1 (nl) 2008-06-02
TR200002615T2 (tr) 2001-01-22
NO20003304L (no) 2000-08-21
HU229596B1 (en) 2014-02-28
SK287123B6 (sk) 2009-12-07
NO326265B1 (no) 2008-10-27
NO20003304D0 (no) 2000-06-23
KR100520737B1 (ko) 2005-10-12
EP0933372A1 (fr) 1999-08-04
FR08C0015I2 (fr) 2009-10-30
EP0933372B1 (fr) 2007-12-26
EP1944300A2 (fr) 2008-07-16
NO2009008I2 (fr) 2010-09-27
AR017965A1 (es) 2001-10-24
EA200000703A1 (ru) 2000-12-25
NL300339I2 (nl) 2009-11-02
LU91426I2 (fr) 2008-06-02
US20100124543A1 (en) 2010-05-20
CN101565412A (zh) 2009-10-28
JP2005350478A (ja) 2005-12-22
PT933372E (pt) 2008-03-31
US7592368B2 (en) 2009-09-22
DE69838903T2 (de) 2008-09-18
JPH11209337A (ja) 1999-08-03
CO4990992A1 (es) 2000-12-26
US20050148548A1 (en) 2005-07-07
OA11468A (en) 2004-05-05
BG104631A (en) 2001-02-28
US6436989B1 (en) 2002-08-20
ME00561B (me) 2011-10-10
EA003509B1 (ru) 2003-06-26
DE69838903D1 (de) 2008-02-07
JP4282639B2 (ja) 2009-06-24
EE200000385A (et) 2001-12-17
IL136941A0 (en) 2001-06-14
AU6546698A (en) 1999-07-19
SK9662000A3 (en) 2001-02-12
DE122008000021I2 (de) 2010-02-04
RS52483B (en) 2013-02-28
EE04466B1 (et) 2005-04-15
MEP82008A (en) 2011-12-20
DE122008000021I1 (de) 2008-08-14
JP2009102400A (ja) 2009-05-14
JP3736964B2 (ja) 2006-01-18
MY131525A (en) 2007-08-30
IS2817B (is) 2012-11-15
PE20000048A1 (es) 2000-02-08
CN100503589C (zh) 2009-06-24
NO2009008I1 (fr) 2009-05-04
CZ20002363A3 (cs) 2000-11-15
PL342113A1 (en) 2001-05-21
AU755087B2 (en) 2002-12-05
CZ301653B6 (cs) 2010-05-12
AP2000001850A0 (en) 2000-06-30
CA2231700A1 (fr) 1999-06-24
ES2299193T3 (es) 2008-05-16
KR20010033600A (ko) 2001-04-25
US6838474B2 (en) 2005-01-04
CA2231700C (fr) 2005-08-09
EP1944300A3 (fr) 2008-11-05
SI0933372T1 (sl) 2008-06-30
LU91426I9 (fr) 2018-12-28
TW486474B (en) 2002-05-11
AP1172A (en) 2003-06-30
BR9814480A (pt) 2001-09-25
ID24962A (id) 2000-08-31
ATE382042T1 (de) 2008-01-15
HK1021737A1 (en) 2000-06-30
IS5546A (is) 2000-06-22

Similar Documents

Publication Publication Date Title
BE2018C032I2 (fr)
FR08C0015I1 (fr)
IN187998B (fr)
CH0944937H2 (fr)
IN186470B (fr)
IN186867B (fr)
IN183465B (fr)
IN190966B (fr)
ITMI971012A0 (fr)
IN187711B (fr)
ITMI971042A0 (fr)
BE2013C047I2 (fr)
ITTO970094V0 (fr)
ITAR970020A0 (fr)
ECSDI970399S (fr)
ITVR970026V0 (fr)
IN185037B (fr)
IN185743B (fr)
BR9700653A (fr)
BR9701757A (fr)
ITVR970014V0 (fr)
ITVI970030V0 (fr)
ITVE970027V0 (fr)
IN189107B (fr)
ITMI971281A0 (fr)